COLUMBUS , Ohio -- A new study shows that the activity of a particular gene can identify people who have a more lethal form of acute myeloid leukemia, singling out those patients who should receive more intense therapy.
The gene, called ERG (for ETS-related gene), has also been linked to chronic leukemia and to breast and prostate cancer.
The findings apply to acute myeloid leukemia (AML) patients with leukemia cells that have normal-looking chromosomes, a feature that occurs in about half of AML patients.
Among these patients, those with leukemia cells showing high ERG activity are almost six times more likely to relapse or die within five years than are patients with low ERG expression following standard therapy.
The Cancer and Leukemia Group B study was initiated by researchers at the Ohio State University Comprehensive Cancer Center, and their findings were published online in the Journal of Clinical Oncology.
Our study shows that high ERG activity predicts a poor prognosis in these patients, even when other molecular markers are taken into consideration, says first author Guido Marcucci, associate professor of internal medicine and an AML specialist at Ohio State's James Cancer Hospital and Solove Research Institute.
The findings mean that these patients require a stem-cell transplant or other aggressive therapy, and that patients with low ERG activity can be treated using standard therapy.
The research confirms a 2005 study led by the same Ohio State researchers in a completely independent set of patients, Marcucci says.
Both studies together further refine the molecular classification of AML in this group of patients and should help us improve treatment outcomes, says principal investigator Clara D. Bloomfield, professor of internal medicine, and an internationally recognized specialist in AML.